Also known as: NCI
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
PDS Biotechnology announced positive interim Phase 2 Stage 1 data for PDS01ADC plus HAIP in MSS/pMMR colorectal liver metastases. The trial showed a 77.8% objective response rate and about 85% 24-month survival in 9 patients.
A study published in The Journal of Clinical Investigation found that CXCL11 may help drive endocrine resistance in some hormone receptor-positive breast cancers. Researchers said ED-resistant tumors had increased immune signaling and may be more responsive to immunotherapies.
Ataraxis AI has launched Ataraxis Breast CTX, an AI test that predicts individualized chemotherapy benefit for breast cancer patients. The tool uses digital pathology and clinical data to estimate patient-level outcomes with and without chemotherapy, moving beyond population averages. The test has been validated across studies involving over 10,000 patients and is now available through CLIA-certified laboratories.
A secondary analysis of the Southwest Oncology Group S1609 trial found that larger baseline tumor burden correlated with shorter overall survival but not progression-free survival in rare cancer patients treated with nivolumab plus ipilimumab. The study of 722 patients showed tumor burden was independently associated with survival outcomes but not predictive of tumor regression after dual immunotherapy.
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Research communities in the US and UK face funding disruptions as governments demand greater alignment with national priorities. UKRI has paused grant programs while early-career researchers advocate for increased NIH funding.
